Bascones-Martinez A, Mattila R, Gomez-Font R, Meurman JH. Immunomodulatory drugs: Oral and systemic adverse effects. Med Oral Patol
Oral Cir Bucal. 2014 Jan 1;19 (1):e24-31.
doi:10.4317/medoral.19087
http://dx.doi.org/doi:10.4317/medoral.19087
|
1. Avorn J. Learning about the Safety of Drugs. A
Half-Century of Evolution. N Engl J Med. 2011;365:2151-3. |
|
|
|
|
|
2. Asherson RA, Gunter K, Daya D, Shoenfeld Y. Multiple Autoimmune Diseases in a Young
Woman: Tuberculosis and Splenectomy as Possible Triggering
Factors? Another Example of the "Mosaic" of Autoimmunity. J Rheumatol. 2008;35:1224-7. |
|
|
|
|
|
3. Chan
LS. Ocular and oral mucous membrane pemphigoid (cicatricial pemphigoid). Clin Dermatol. 2012;30:34-7. |
|
|
|
|
|
4. Carsons SE. Issues Related to Clinical Trials of Oral and
Biologic Disease-Modifying Agents for Sjögren's
Syndrome. Rheum Dis Clin
North Am. 2008;34:1011-23. |
|
|
|
|
|
5. Lee SJ,
Chinen J, Kavanaugh A. Immunomodulator therapy: monoclonal antibodies, fusion
proteins, cytokines, and immunoglobulins. J Allergy
Clin Immunol. 2010;125:S314-23. |
|
|
|
|
|
6. Preiss JC, Zeitz M. Use of methotrexate in patients with inflammatory bowel
diseases. Clin Exp Rheumatol. 2010;28:S151-5. |
|
|
|
|
|
7. Keystone
EC. Does Anti-Tumor Necrosis Factor-α Therapy Affect Risk of
Serious Infection and Cancer in Patients with Rheumatoid Arthritis?: A Review of Longterm Data. J Rheumatol. 2011;38:1552-62. |
|
|
|
|
|
8. Miller
E, Ernst J. Anti-TNF immunotherapy and tuberculosis reactivation: another
mechanism revealed. J Clin Invest. 2009;119:1079-82. |
|
|
|
|
|
9. Schonder
KS, Mazariegos GV, Weber RJ. Adverse Effects of Immunosuppression in Pediatric Solid Organ
Transplantation. Pediatr Drugs. 2010;12:35-49. |
|
|
|
|
|
10. Gaffen SL, Hajishengallis G. A
new inflammatory cytokine on the block: re-thinking periodontal disease and
the Th1/Th2 paradigm in the context of Th17 cells and IL-17. J Dent Res. 2008;87:817-28. |
|
|
|
|
|
11.
Bradford K, Shih D. Optimizing 6-mercaptopurine and azathioprine
therapy in the management of inflammatory bowel disease. World J Gastroenterol. 2011;17:4166-73. |
|
|
|
|
|
12. Koller A, Denhaerynck K, Moons
P, Steiger J, Bock A, De Geest
S. Distress associated with adverse effects of immunosuppressive medication
in kidney transplant recipients. Prog Transplant.
2010;20:40-6. |
|
|
|
|
|
13.
Andrews JM, Travis SPL, Gibson PR, Gasche C.
Systematic review: does concurrent therapy with 5-ASA and immunomodulators
in inflammatory bowel disease improve outcomes?.
Aliment Pharmacol Ther.
2009;29:459-69. |
|
|
|
|
|
14. Schuna AA, Megeff C. New drugs
for the treatment of rheumatoid arthritis. Am
J Health Syst Pharm. 2000;57:225-34. |
|
|
|
|
|
15. Toscano E, Cotta
J, Robles M, Lucena MI, Andrade RJ. Toxicidad hepática inducida por los
nuevos fármacos inmunosupresores. Gastroenterol Hepatol. 2010;33:54-65. |
|
|
|
|
|
16. Prokai A, Fekete A, Pasti K, Rusai K, Banki N, Reusz G, et al. The
importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus. Pediatr Diabetes.
2012;13:81-91. |
|
|
|
|
|
17. López-Jornet P, Camacho-Alonso F, Salazar-Sanchez N.
Topical tacrolimus and pimecrolimus
in the treatment of oral lichen planus: an update.
J Oral Pathol Med. 2010;39:201-5. |
|
|
|
|
|
18. Ben Dhaou
B, Boussema F, Aydi Z, Baili L, Tira H, Cherif O, et
al. Corticosteroid-associated complications
in elderly. Tunis Med. 2012;90:774-7. |
|
|
|
|
|
19. Srinivas TR, Meier-Kriesche HU.
Minimizing Immunosuppression, an Alternative
Approach to Reducing Side Effects: Objectives and Interim Result. Clin J Am Soc Nephrol. 2008;3:S101-16. |
|
|
|
|
|
20. Skaar DD, O'Connor H. Potentially serious drug-drug
interactions among community-dwelling older adult dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112:153-60. |
|
|
|
|
|
21. Hersh EV, Moore PA. Adverse drug interactions in dentistry.
Periodontol 2000. 2008;46:109-42. |
|
|
|
|
|
22. Schmitt
C, Kuhn B, Zhang X, Kivitz A, Grange S.
Disease-drug-drug interaction involving tocilizumab
and simvastatin in patients with rheumatoid
arthritis. Clin Pharmacol Ther. 2011;89:735-40. |
|
|
|
|
|
23. Gubbins PO, Heldenbrand S.
Clinically relevant drug interactions of current antifungal agents. Mycoses. 2010;53:95-113. |
|
|
|
|
|
24. Ramos-e-Silva M, Ferreira A,
de-Moura-Castro JC. Oral involvement in autoimmune bullous diseases. Clin Dermatol.
2011;29:443-54. |
|
|
|
|
|
25. Arisawa E, Almeida J, Carvalho
Y, Cabral L. Clinicopathological analysis of oral
mucous autoimmune disease. Med Oral Patol Oral Cir Bucal. 2008;13:E94-7. |
|
|
|
|
|
26. Gottenberg J. Primary Sjögren's
syndrome: Pathophysiological, clinical and
therapeutic advances. Joint Bone Spine. 2009;76:591-4. |
|
|
|
|
|
27.
Mariette X. Therapeutic Potential for B-Cell Modulation in Sjögren's Syndrome. Rheum Dis Clin North Am. 2008;34:1025-33. |
|
|
|
|
|
28. Bowman
S. Biologic Therapies in Primary Sjögren's
syndrome. Curr Pharm Biotechnol. 2012;13:1997-2008. |
|
|
|
|
|
29. Pijpe J, Meijer JM, Bootsma H,
van der Wal JE, Spijkervet FKL, Kallenberg CGM,
et al. Clinical and histologic evidence of salivary
gland restoration supports the efficacy of rituximab
treatment in Sjögren's syndrome. Arthritis Rheum. 2009;60:3251-6. |
|
|
|
|
|
30. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, et al. Reduction of fatigue in Sjögren syndrome with rituximab:
results of a randomised, double-blind,
placebo-controlled pilot study. Ann Rheum Dis. 2008;67:1541-4. |
|
|
|
|
|
31. Meijer
JM, Meiners PM, Vissink
A, Spijkervet FKL, Abdulahad
W, Kamminga N, et al. Effectiveness of rituximab treatment in primary Sjögren's
syndrome: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:960-8. |
|
|
|
|
|
32.
Ramos-Casals M, Tzioufas A, Stone J, Siso A, Bosch X. Treatment of primary Sjogren
Sybdrome: a systematic review. JAMA. 2010;304:452-60. |
|
|
|
|
|
33. Yarom N. Etanercept for the
management of oral lichen planus. Am J Clin Dermatol.
2007;8:121. |
|
|
|
|
|
34. Cheng
A, Mann C. Oral erosive lichen planus treated with efalizumab. Arch Dermatol.
2006;142:680-2. |
|
|
|
|
|
35. Asarch A, Gottlieb A, Lee J, Masterpol
K, Scheinman P, Stadecker
M, et al. Lichen planus-like eruptions: an emerging
side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol. 2009;61:104-11. |
|
|
|
|
|
36. Mocciaro F, Orlando A, Renna S,
Rizzuto M, Cottone M.
Oral lichen planus after certolizumab
pegol treatment in a patient with Crohn's disease. J Crohns
Colitis. 2011;5:173-4. |
|
|
|
|
|
37. Aringer M, Houssiau F, Gordon
C, Graninger WB, Voll RE,
Rath E, et al. Adverse events and efficacy of TNF-α blockade
with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology.
2009;48:1451-4. |
|
|
|
|
|
38. Uppal SS, Hayat SJ, Raghupathy R. Efficacy and safety of infliximab
in active SLE: a pilot study. Lupus.
2009;18:690-7. |
|
|
|
|
|
39. Vital
EM, Dass S, Buch MH, Henshaw K, Pease CT, Martin MF, et al. B cell biomarkers
of rituximab responses in systemic lupus erythematosus. Arthritis Rheum.
2011;63:3038-47. |
|
|
|
|
|
40.
Terrier B, Amoura Z, Ravaud
P, Hachulla E, Jouenne R,
Combe B, et al. Safety and efficacy of rituximab in systemic lupus erythematosus:
Results from 136 patients from the French autoimmunity and rituximab registry. Arthritis Rheum.
2010;62:2458-66. |
|
|
|
|
|
41. Merrill
JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, et al. The efficacy and safety of abatacept in patients with non?life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter,
exploratory, phase IIb, randomized, double-blind,
placebo-controlled trial. Arthritis Rheum. 2010;62:3077-87. |
|
|
|
|
|
42. Iwata
S, Saito K, Tokunaga M, Tanaka Y. B cell or T cell-dominant recurrence after rituximab therapy in patients with SLE. Ann Rheum Dis. 2012;71:1749-50. |
|
|
|
|
|
43.
Lazarus MN, Turner-Stokes T, Chavele KM, Isenberg
DA, Ehrenstein MR. B-cell numbers and phenotype at
clinical relapse following rituximab therapy differ
in SLE patients according to anti-dsDNA antibody
levels. Rheumatology. 2012;51:1208-15. |
|
|
|
|
|
44. Chun
H, Chung J, Kim H, Yun J, Jeon
J, Ye Y, et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007;27:461-6. |
|
|
|
|
|
45. Illei
GG, Shirota Y, Yarboro
CH, Daruwalla J, Tackey
E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and
impact on circulating plasma cells from an open-label phase
I dosage-escalation study. Arthritis Rheum. 2010;62:542-52. |
|
|
|
|
|
46. Del Valle AE, Martínez-Sahuquillo A, Padrón JR, Urizar
JM. Two cases
of linear IgA disease with clinical manifestations
limited to the gingiva. J Periodontol. 2003;74:879-82. |
|
|
|
|
|
47. Perez-Alvarez
R, Pérez-de-Lis M, Ramos-Casals M. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25:56-64. |
|